再発性低悪性度非ホジキンリンパ腫（iNHL）におけるコパンリシブと標準免疫化学療法との併用に関する研究

基本情報

NCT ID

NCT02626455

ステータス

中止

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

551

治験依頼者名

Bayer

概要

The purpose of this study is to assess whether copanlisib in combination with standard immunochemotherapy (rituximab in combination with bendamustine \[R-B\] and rituximab in combination with a 4 drug combination of cyclophosphamide, doxorubicin, vincristine and prednisone/prednisolone \[R-CHOP\]) is effective and safe, compared with placebo in combination with standard immunochemotherapy (R-B or R-CHOP) in patients with relapsed iNHL who have received at least one, but at most three, lines of treatment, including rituximab-based immunochemotherapy and alkylating agents.

対象疾患

介入

依頼者（Sponsor）

実施施設 (20)